Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Martin

Showing results (341-350 of 361) with videos related to

Pageof 37
Sort By:
Journal for Immunotherapy of Cancer|March 6, 2026
Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myelomaMagdalena Corona, Roberto García-Vicente, Adolfo Jesús Saez-Marin, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 15, 2023
NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022Ayman Saad, Alison Loren, Javier Bolaños-Meade, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 11, 2023
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 9, 2025
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025Shaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 20, 2024
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Nature Communications|December 10, 2015
Corrigendum: Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patientsElad Ziv, Eric Dean, Donglei Hu, et al.
Nature Communications|July 23, 2015
Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patientsElad Ziv, Eric Dean, Donglei Hu, et al.
Biorxiv : the Preprint Server for Biology|May 4, 2026
Development of a Fully Non-Viral 1XX-enhanced BCMA CAR-T Cell Therapy for Multiple MyelomaAlexis Talbot, Ke Li, Jae Hyun J Lee, et al.
The Lancet. Haematology|February 3, 2022
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working GroupNoopur S Raje, Elias Anaissie, Shaji K Kumar, et al.
Lancet (London, England)|June 27, 2021
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyJesus G Berdeja, Deepu Madduri, Saad Z Usmani, et al.
Pageof 37

Showing results (341-350 of 361) with videos related to

Sort By:
Pageof 37
Journal for Immunotherapy of Cancer|March 6, 2026
Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myelomaMagdalena Corona, Roberto García-Vicente, Adolfo Jesús Saez-Marin, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 15, 2023
NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022Ayman Saad, Alison Loren, Javier Bolaños-Meade, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 11, 2023
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 9, 2025
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025Shaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 20, 2024
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Nature Communications|December 10, 2015
Corrigendum: Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patientsElad Ziv, Eric Dean, Donglei Hu, et al.
Nature Communications|July 23, 2015
Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patientsElad Ziv, Eric Dean, Donglei Hu, et al.
Biorxiv : the Preprint Server for Biology|May 4, 2026
Development of a Fully Non-Viral 1XX-enhanced BCMA CAR-T Cell Therapy for Multiple MyelomaAlexis Talbot, Ke Li, Jae Hyun J Lee, et al.
The Lancet. Haematology|February 3, 2022
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working GroupNoopur S Raje, Elias Anaissie, Shaji K Kumar, et al.
Lancet (London, England)|June 27, 2021
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyJesus G Berdeja, Deepu Madduri, Saad Z Usmani, et al.
Pageof 37